Research of Electrical Current Against Viruses
Biocompatible Electric Current Attenuates HIV-1 Infectivity
PATENT 5,139,684; Electrically conductive methods and systems for treatment of blood
BIOCOMPATIBLE ELECTRIC CURRENT ATTENUATES HIV-1 INFECTIVITY
William D. Lyman, Irwin R. Merkatz
William C. Hatch and Steven C. Kaali
Departments of Pathology, and Obstetrics & Gyneclogy
Albert Einstein College of Medicine,
1300 Morris Park Ave. Bronx, N.Y. 10461
Summary
In this report, we present the results of double-blinded studies on the use of direct electric current to alter the infectivity of HIV-1 for susceptible cells in vitro. These experimental currents were equal to 3.85 and 7.7µA/mm2 current densities respectively. The reduction of infectivity was dependent upon the total electric charge (µA x min) passing through the chamber to which the virus was exposed. Viral infectivity was determined by two independent measures: a syncytium-formation assay which can be used to quantify the production of infectious particles; and a reverse transcriptase assay which is an index of viral protein production.
Results
Syncytium-formation assay:
Using this index of HIV-1 infectivity, it was determined that exposing virus to direct electric current suppressed its capacity to induce the formation of syncytia. Figure 1 shows a representative experiment and Table 2 shows the Croup data for 3 separate experiments. As can be noted in Figure 1, a statistically significant (p<0.001) reduction in syncytium number was absented and this reduction was dependent upon the current applied to the viral isolate. At three different viral dilutions, there were analogous results in that a total charge of 200µA x min (25µA for 8 minutes) reduced the number of syncytia from 50% to 65% while a charge of 3O0µA x min (50µA for 6 minutes, 75µA for 4 minutes or 100µA for 3 minutes) resulted in 90% reduction.
Reverse transcriptase assay:
The direct electric currents to which HIV-l was exposed also reduced reverse transcriptase activity. Five separate experiments were conducted and a representative experiment is shown in Figure 2 and the data are included in Table 3. As can be seen in Figure 2, there was a significant decrease in the amount of reverse transcriptase activity after exposure of the virus to either 50A for 3 or 6 minutes. An equivalent reduction in reverse transcriptase activity was also noted with exposure to 100µA for 3 minutes and almost ablation of reverse transcriptase activity was seen with exposure of the viral isolate to 100µA for 6 minutes. The group data (Table 3) show that after exposure to 50µA for 6 minutes, there was a 44% reduction in activity and treatment of virus with 100µA for 6 minutes resulted in a 94% reduction. An analysis of variance indicates that the decrease in reverse transcriptase activity was statistically significant (p<0.0001).
DISCUSSION
The results reported here demonstrate that HIV-1 treated with direct electric currents from 50 to 100µA has a significantly reduced infectivity for susceptible cells in vitro. This reduction of infectivity correlates with the total electric charge passing through the chamber. The therapeutic potential of electric current may reside in its ability to lower the viral titer to subclinical significance or in its incorporation into a strategy analogous to that of other therapies in which repeated cycles of treatment eventually achieve remission or cure. It may be also feasible to treat AIDS patients with direct electric current using either extracorporeal [out of body] systems or self contained indwelling electrodes.
Figure l
Syncytium Formation at 1:160 dilution
exposure (µA/minute) 0/6 25/8 50/6 75/4 100/3
# of syncytium formed 128 45 9 7 2
Five aliquots of the RF strain of HIV-1 were exposed to direct electric current. At all the dilutions tested, electrical treatment of the virus aliquots resulted in a significant decrease in syncytium formation.
Figure 2
Reverse Transcriptase Activity exposure (µA/minute) 0/3 0/6 50/3 50/6 100/3 100/6
reverse transcriptase 300 205 108 105 100 12 count per million x 10-3
Six aliquots of the RF strain of HIV-1 were exposed to different amounts of current for 3 or 6 minutes. A significant decrease (p<0.005) from 0 current levels (0/3 and 0/6) in reverse transcriptase activity is noted. However, the decrease is more significant (p<0.0001) when virus is exposed to 100µA for 6 minutes.
BioElectric's Notes:
Human CD4 immune blood cells were exposed to various amounts of electric current for various amounts of time and then mixed with HIV-1 virus. The resultant decrease in CD4 infection by the virus (resulting in cell enlargement [syncytium] and reverse transcriptase production) is listed in the two tables under the column headings indicating how much electric current in microamperes (µA= millionths of an ampere) was applied to the virus for how many minutes. 100µA applied for 3 minutes to the virus produced only approximately 2% of the number of enlarged cells (syncytium) as was produced after 6 minutes without electrical treatment of the virus. 100µA is equal to 7.7µA per square millimeter (mm2) of the surface of the electrodes delivering the electric current to the virus. Explanation of tests: Human CD4 immune cells, when exposed to HIV-1 virus, normally become infected with the virus and then enlarged as the virus reproduces itself (with the coerced help of the blood cell) within the CD4 cell. So anything that can reduce the viral infectivity (the ability of the virus to infect a cell) can be tested in the laboratory to see if less enlarged cells (syncytium) are produced which will show the degree of success of the anti-viral. Reverse transcriptase is an enzyme used by retroviruses to form a complementary DNA sequence (cDNA) from their RNA. The resulting DNA is then inserted into the chromosome of the host cell. A test showing how much is being produced is a way to quantify approximately how much viral reproduction has happened as a result of viral infection of the CD4 cells. So a test result showing reduced reverse transcriptase activity is one that shows how successful an anti-viral is at reducing the infectivity of a virus.
|
U.S. PATENT 5,139,684
By Steven Kaali and Peter Schwolsky
Filed 11-16-1990, approved 8-18-1992
Electrically conductive methods and systems for treatment of blood and other body fluids and/or synthetic fluids with electric forces
Claimed:
"...applying... no biologically damaging electric potentials... to the electrically conductive electrode segments whereby electric field forces are produced... that induce biologically compatible current flow through the blood... to attenuate bacteria, virus, parasites, fungus contained in the blood... to render the bacteria, virus, parasites, fungus ineffective while not impairing the biological usefulness of the fluids"
Summary:
"...to attenuate such contaminants to the extent that bacteria, virus, or fungus, or parasites contained in the blood... are rendered ineffective to infect or affect healthy cells."
Best Mode of Practicing Invention:
"For example, treatment of AIDS virus in media at 100 microamperes for 3 minutes has been observed to substantially attenuate (render ineffective) the AIDS virus."
Experimental Results:
"In conclusion, these experiments... indicate at a statistically significant level that direct electric current... can attenuate the ability of HIV-1 to infect normally healthy cells which are susceptible to the HIV-1 AIDS virus." "Both of these assays (syncytia & reverse transcriptase) are widely used as reproducible measures of viral infection and can be used to determine if alternations in viral infectivity as a product of this electrical treatment can be detected." "...it is believed obvious that other modifications and variations of the invention will be suggested to those skilled in the art in the light of the above teachings." "...it is possible that certain virus may be attenuated (or attenuated at a faster rate) if they are exposed to a greater electric current magnitude of the order of 500 microamperes for shorter time periods."
BioElectric's Notes:
The patent's 1st laboratory test used electrically treated (at 100µA/3min which is 7.7µA per square millimeter for 3 minutes) HIV-l virus mixed with human T cells (immune cells which the HIV likes to infect) and showed 99% less infected & enlarged T cells (syncytia) by viruses after 4 days compared to T cells mixed with HIV-1 not electrically treated. The patents 2nd lab test used electrically treated (l00µA/6min) HIV-1 mixed with blood T cells and showed 72% less virus associated enzymes (reverse transcriptase produced as a result of viral reproduction) after 4 days, compared to T cells mixed with HIV-1 not treated. The patent stated; "it is possible that certain virus may be attenuated (or attenuated at a faster rate) if they are exposed to a greater electric current magnitude of the order of 500 microamperes for shorter time periods." 500 microamperes (500µA) applied to the experiments electrodes with a surface area of 13.3mm2 yields a current of 38.5µA per square millimeter (38.5µA/mm2). In approximation of this idea, my Microbe Electrifier was estimated to produce 17 to 34µA/mm2 (for 4 - 8 mm2 cross sectional arterial area). This high current is necessary due to the short (but repeated) treatment durations of blood when using an electrode on each wrist. Due to the short durations of exposure to the electricity, as the blood passes through the main arteries (~ 1 minute), it is necessary to do treatments of up to 1 - 2 hours. | Blood Electrification Against Cancer
Bob Beck said "Recently, Jane and I were invited to the largest alternative cancer clinic in the western hemisphere. The man in charge of the clinic told me that 87% of their terminal, not mid-stage, cancer patients, who had been given up for dead, are now healed! They have scar tissue where once they had lesions; they have clean biopsies. They are up, they are back at work. Those patients used the technology we are discussing today (blood electrification). I was given terminal cancer patients by the largest and best-known hospital in California. After 12 of them were healed, some of them ended up committing suicide because we had taken their crutches away from them. We will say that this technology will not overcome a person's death wish. That is an issue we have to find an answer for and have not yet found, but we will."
I don't doubt what Bob said after what I have seen concerning alternative cancer treatment by electrotherapy. When I started to sell the devices one of my first clients reported a lessening of his PSA levels from prostate cancer by using the Beck devices. Years later a Latino friend of mine told me of his recent diagnosis of lymph cancer with tumors all along his lymph system and I told him how to clean up his diet and lifestyle to support his immune system, and loaned him a Microbe Electrifier with instructions on how to use it daily. Two months later he said the tumors were greatly reduced in size and that he felt much better. I lost contact with him, but a year later ran into a friend of his who said that he'd just gotten married and was doing fine. So obviously blood electrification can be used to eliminate the cancer-causing viruses circulating in the blood (via the Microbe Electrifier). HOME
|